Potent irreversible pan ErbB inhibitor (IC50 values are 6.0, 45.7 and 73.7 nM for EGFR, ERBB2 and ERBB4, respectively). Inhibits mutant and wild type forms of ErbB, including EGFR T780M, and shows activity in NSCLC cell lines sensitive and resistant to Iressa (Cat.No. 3000). Inhibits tumor growth. Orally bioavailable.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 469.94. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.13 mL||10.64 mL||21.28 mL|
|5 mM||0.43 mL||2.13 mL||4.26 mL|
|10 mM||0.21 mL||1.06 mL||2.13 mL|
|50 mM||0.04 mL||0.21 mL||0.43 mL|
References are publications that support the biological activity of the product.
Engelman et al (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer.Res. 67 11924 PMID: 18089823
Gonzales et al (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol.Cancer.Ther. 7 1880 PMID: 18606718
Li et al (2017) A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat.Cell.Biol. 19 106 PMID: 28114269
If you know of a relevant reference for Dacomitinib, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dacomitinib, Dacomitinib supplier, Dacomitinib, ErbB, inhibitors, inhibits, EGFR, ERBB2, ERBB4, potent, irreversible, pan-ErbB, cancer, orally, bioavailable, PF00299804, 6231, Tocris Bioscience
Citations for Dacomitinib
Citations are publications that use Tocris products.
Currently there are no citations for Dacomitinib. Do you know of a great paper that uses Dacomitinib from Tocris? Please let us know.
Reviews for Dacomitinib
There are currently no reviews for this product. Be the first to review Dacomitinib and earn rewards!
Have you used Dacomitinib?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.